The biggest change in the fifth batch of volume purchases is here: marketing compliance will lead to the death of pharmaceutical companies!

The fifth batch of bulk purchases officially started.
June 23 is the bid opening date.
If no surprises, the results of the fifth batch of bulk purchases will be announced that day.
After a week of publicity, the fifth batch of bulk purchases will officially be selected.
Will be officially introduced
.

First of all, in the declaration of enterprise qualifications, it is added that the declared enterprise is not included in the current "National Medical Price and Risk Warning List of Untrustworthy Enterprises in Procurement and Procurement"
.

According to the credit evaluation system of the National Medical Insurance Bureau, those who have been assessed as "particularly serious" for dishonesty by 5 or more provinces will be summarized in the "National Medical Price and Risk Warning List of Recruiting Untrustworthy Enterprises", and will be announced once a year in the first quarter of each year.
Last year's credit rating results
.

Secondly, in the bidding conditions, the document is clear, and when the "comparable price" of the same type of enterprise is the same, it shall be determined in sequence according to the following rules:

1.
Enterprises that have not been rated as "medium", "serious" or "particularly serious" by any province based on the medical price and recruitment credit evaluation system are preferred;

2.
In 2020, enterprises with a large number of provincial supply regions will be given priority (based on data submitted by various regions);

3.
In 2020, the enterprises with large sales volume in various regions will be given priority, and the sales volume of multiple specifications and varieties will be combined and calculated (based on the data submitted by each region)
.

These three items are the parts that have changed from the previous ones.
It can be seen that, on the one hand, as mentioned above, credit evaluation has become the threshold for pharmaceutical companies, which directly affects the selection.
On the other hand, 2 and 3 are actively drawing on the provincial level.
With volume procurement rules, the higher and larger the original market share of pharmaceutical companies, the more advantageous they will be
.

In addition, the fifth batch of volume purchases also specifically listed the conditions that can be rejected by the province, and the document is clear:

When the selected company has the following circumstances, the selected province has the right to reject the company's choice:

(1) The enterprise to be selected is rated as "serious" or "particularly serious" by the province based on the medical price and recruitment credit evaluation system
.

(2) The selected company refuses to sign a purchase agreement in the province or refuses to perform the agreement in the province after being selected in the provincial or inter-provincial alliance's centralized drug purchase
.

The national credit evaluation system has taken off, a large number of pharmaceutical companies have been withdrawn from the Internet because they have not signed a letter of integrity marketing commitment, and their recruitment accounts have been cancelled.
Compliance marketing has become a life-and-death line for pharmaceutical companies! The essence of academic promotion is the transmission of medical information, interesting academics, helping pharmaceutical companies to transform their marketing, returning to true academics, digitally displaying the academic promotion process, reviewing the effect of academic concept transmission at any time, and insight into the results of academic concepts
.